The global extracellular vesicles (EV)-based liquid biopsy market is projected to grow steadily from USD 122.72 million in 2025 to approximately USD 149.66 million by 2034, expanding at a CAGR of 2.23%. This growth is fueled by rising demand for minimally invasive diagnostic tools and increasing prevalence of cancer worldwide. North America currently dominates the market, while the Asia Pacific region is emerging as the fastest-growing market segment.
Extracellular Vesicles-Based Liquid Biopsy Market Key Highlights
-
The market value is anticipated to reach USD 149.66 million by 2034, starting from USD 122.72 million in 2025.
-
North America held the largest market share of 48.4% in 2024.
-
Asia Pacific exhibits the fastest CAGR of 15.5% from 2025 to 2034.
-
Exosomes constitute the largest vesicle type segment with 54.3% market share in 2024.
-
The oncology application segment dominates with 48.2% of the market.
-
RNA biomarkers represent the leading biomarker type at 51.8% market share.
-
Academic and research institutes are the primary end-users, holding 46.5% of the market.
-
Key players include Thermo Fisher Scientific, QIAGEN, Bio-Techne, Codiak BioSciences, and others.
Market Revenue Breakdown
| Segment | Market Share (2024) | CAGR (2025-2034) |
|---|---|---|
| Exosomes (Vesicle) | 54.3% | – |
| Apoptotic Bodies | – | 14.2% |
| Kits & Reagents | 54.4% | – |
| Services | – | 14.4% |
| Oncology (Application) | 48.2% | – |
| Neurology | – | 14.8% |
| RNA Biomarkers | 51.8% | – |
| DNA Biomarkers | – | 14.6% |
| Academic & Research (End User) | 46.5% | – |
| Hospitals & Diagnostics | – | 14.7% |
What Role Does AI Play in the Extracellular Vesicles-Based Liquid Biopsy Market?
Artificial intelligence is rapidly enhancing the EV liquid biopsy field by enabling sophisticated biomarker profiling and predictive modeling. AI-powered data analytics improve diagnostic accuracy and early disease detection, particularly in oncology and neurology. The integration of AI in EV workflows supports real-time analysis, automation, and multi-omics data integration, propelling personalized medicine applications.
Market Growth Drivers
The market growth is driven by increasing global cancer incidence, rising investments in EV research, and expanding clinical adoption of non-invasive liquid biopsy technologies. Advances in EV isolation methods (microfluidics, immunoaffinity) and detection platforms (electro-optical, nano plasmonics) are enhancing test sensitivity and throughput. Government initiatives and healthcare expenditure, particularly in Asia Pacific, further support rapid expansion.
Emerging Opportunities and Market Trends
What are the new trends shaping the EV-based liquid biopsy market?
How is the Asia Pacific region influencing market dynamics?
The region is the fastest-growing market, spurred by healthcare advancements, government support, and rising adoption of precision medicine.
Which EV biomarkers are gaining prominence?
DNA biomarkers are growing rapidly due to their role in mutation detection and minimal residual disease monitoring alongside established RNA and protein biomarkers.
How are startups and new technologies impacting the market?
Innovative companies like Mursla Bio have launched AI-driven EV detection platforms, unlocking ultra-sensitive diagnostics for early cancer detection and organ-specific monitoring.
Regional and Segment Analysis
North America leads with dominant market share owing to early approvals, vigorous R&D, and a robust biotech ecosystem. The U.S. is the principal contributor, with strong healthcare infrastructure supporting innovation. In contrast, Asia Pacific’s rising government initiatives and cancer awareness campaigns position it as the most dynamic growth market.
Segment-wise, exosomes remain the preferred vesicle type for diagnostics due to their abundance and molecular cargo. Oncology dominates application usage, followed by rapidly growing neurology. Academic and research institutes currently drive demand, while hospitals show strong adoption growth.
Latest Breakthroughs and Leading Companies
Notable innovations include Mursla Bio’s launch of NEXOS, an electro-optical EV detection system with FDA Breakthrough Device Designation for cancer diagnosis. Key companies actively shaping the market include Thermo Fisher Scientific, QIAGEN, Bio-Techne, Codiak BioSciences, Illumina, NanoView Biosciences, and Evox Therapeutics.
What Are the Major Challenges and Cost Pressures?
Despite technological advancements, high costs of sophisticated EV isolation instruments and standardization hurdles limit broad clinical adoption. Reimbursement complexities and regulatory uncertainties also pose challenges. Addressing these will require collaborative efforts among industry stakeholders, regulatory bodies, and payers.
Case Study: Mursla Bio’s NEXOS System
Mursla Bio introduced the NEXOS platform in June 2024, integrating electro-optical and electrical detection to achieve unprecedented sensitivity in EV subtype quantification. Its application in liver cancer surveillance has earned FDA Breakthrough Device Designation, demonstrating clinical reliability in early disease detection and therapy monitoring.
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7121
You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344